GC Pharma and Shincheonji Church are offering assistance for the Latin American countries ravaged by the COVID-19 pandemic. A recent breakthrough in GC Pharma’s COVID-19 research was achieved on Dec. 6, 2020, when a COVID-19 patient recovered after receiving GC Pharma’s blood plasma therapy. The therapy, GC5131, was developed by fractioning an antibody with the immunogenicity from the plasma of a recovered COVID-19 patient. Many Latin American hospitals already use GC Pharma’s IVIG-SN treatment to save patients from various illnesses, and this breakthrough may also open doors for GC Pharma’s blood plasma therapy to be administered to Latin American COVID-19 patients. In addition, Shincheonji Church provided a boost to GC Pharma’s COVID-19 treatment research through large-scale plasma donations. A total of 4,000 Shincheonji members are expected to participate in the plasma donation, which is now in its third round. “For the people around the world, [donating our blood] for a cure is the most valuable thing we can do after recovering from COVID-19,” said a member of Shincheonji Church.
To view the full press release, visit https://ibn.fm/YSP8m
About GC Pharma
GC Pharma, a biotechnology pioneer in South Korea, is now preparing to take another major leap forward toward ensuring a healthier and happier future for all peoples worldwide. Challenge and innovation, care and compassion, transparency and integrity, and respect and dedication are the core principles that guide GC Pharma on its journey toward achieving its next goal. For more information, visit www.GlobalGreenCross.com.
About Shincheonji Church
Shincheonji, Church of Jesus, the Temple of the Tabernacle of the Testimony, commonly known as Shincheonji Church, Shincheonji Church of Jesus or simply Shincheonji, is an offshoot Christian new religious movement established in South Korea by Lee Man-hee. For more information, visit http://en.Shincheonji.kr.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork